Moderna cancer vaccine cuts melanoma recurrence or death by 42%
Moderna’s experimental cancer vaccine reduced melanoma recurrence or death by 42% after two years, but a data leak triggered a sharp sell-the-news reaction. The setup now turns on whether the clinical result can outweigh near-term skepticism around the disclosure and Moderna’s loss-making base.
The story
The experimental treatment, developed for melanoma, helped prevent cancer from returning or death by 42% after two years. The result was followed by a sell-the-news reaction after a data leak rattled investors, sending Moderna’s shares lower.
The result arrives against a difficult operating backdrop. Moderna recorded $1.9 billion of revenue in fiscal 2025, down 39.9% year over year, and reported a net margin of -145.2% with diluted EPS of $-7.26.
For Moderna, the mechanism is the potential expansion of its product pipeline beyond vaccines already on the market: a lower recurrence or mortality rate could support further development of the melanoma treatment and its eventual commercial value. The immediate market reaction instead shows that investors were focused on the leak and the timing of the data release.
The two-year result is a clinical milestone, not yet a commercial outcome. The size and durability of any future opportunity, the next regulatory steps and the effect of the disclosure issue remain open questions.
The next decisive evidence would be additional clinical detail and a dated regulatory or development update for the melanoma program.
Our read · Thu, Oct 22
A two-year melanoma readout showed Moderna’s vaccine cut recurrence or death by 42%.
Why. The clinical result could add value to Moderna’s pipeline, but the sell-the-news reaction and data-leak overhang offset that read for now. The company’s $1.9 billion of 2025 revenue fell 39.9% year over year, alongside a -145.2% net margin and $-7.26 diluted EPS, leaving the melanoma program to carry greater strategic weight without a dated next catalyst to support a directional call.
Both cases
What could change this view: The read could weaken if later clinical detail reduces confidence in the 42% benefit or if the disclosure issue continues to overshadow the result.
Who reported it · 2
Related by name
Keep reading
More on MRNA
Moderna (MRNA), Merck (MRK) Cancer Vaccine Wins in Late-Stage TrialModerna shares surge 179% on melanoma therapy; revenue fell 39.9% to $1.9BModerna revenue fell 39.9% to $1.9B in FY with -145.2% net marginLatest on the Wire
SMCI files 10-Q — Quarterly Report: 10-QHims ends GLP-1 compounding in Lilly deal as shares rallyUS adds 165,000 jobs in October as wages rise and unemployment fallsTrump weighs renewed Iran strikes as negotiators review a new proposalBitcoin holds $76,000 as Nasdaq futures rebound 1.5% before jobs dataContinue on the Wire →Latest on the Wire
Bitcoin holds $76,000 as Nasdaq futures rebound 1.5% before jobs dataFed holds rates as stable labor market keeps December hike on trackTesla to wind down Cybertruck production as Musk pivots to roboticsFormer BOJ economist sees December hike and 2% terminal rateContinue on the Wire →Top this week
Democrats sweep Congress, setting Trump up for legislative gridlockFutures rebound after blue sweep as dollar slides and gold tops $4,000Bitcoin plunges as AI chip selling drags Nasdaq down more than 2%Trump’s Republican Party faces a midterm verdict from US voters todayBitcoin faces renewed pressure as Binance hack intensifies market fearAbout this report
Reported by MarketWatch as Moderna’s cancer vaccine hits its targets, but a data leak rattled investors and the stock tumbled
, . Who answers for this
2 reports from 2 publishers in this record. Closes are licensed end-of-day data from Databento; the move after a story is its first close against the close before it. How this is decided →
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →